> ## Content Index
> Fetch the complete content index at: https://psychedelicmentalhealth.net/llms.txt
> Use this file to discover other available public pages before exploring further.

# Spotlight: Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression (Kachlick, et al, 2025)
- URL: https://psychedelicmentalhealth.net/spotlight-nonresponse-to-ketamine-in-treatment-resistant-bipolar-depression-kachlick-et-al-2025/
- Published: 2025-08-30T19:45:39.000Z
- Updated: 2025-08-30T19:45:39.000Z
- Description: Ketamine demonstrates a favorable safety and tolerability profile for short time use in TRBD regardless of isolated baseline characteristics, although a more severe comorbidity burden and benzodiazepine use appear to be associated with nonresponse.
- Author: Michael DeMarco, PhD
- Tags: ketamine, non-response, bipolar depression, ketamine safety, ketamine research, research, ketamine non-responder, benzodiazepine

[Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression - PubMedNCT04226963 and NCT05565352.![](https://storage.ghost.io/c/61/a8/61a8484e-df24-47fb-903c-d012ff10c983/content/images/icon/favicon-192-86.png)PubMedZofia Kachlik![](https://storage.ghost.io/c/61/a8/61a8484e-df24-47fb-903c-d012ff10c983/content/images/thumbnail/pubmed-meta-image-v2-85.jpg)](https://pubmed.ncbi.nlm.nih.gov/40879542/)

(2025) Ketamine is a prototypical rapid-acting antidepressant for treatment-resistant bipolar depression (TRBD), yet many patients do not achieve a meaningful response.